Spyre Therapeutics took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Spyre Therapeutics Plunges; Why Analysts Aren't Sweating ·
Investor's Business Daily
